The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy.

MLA

D’Andrea, M., et al. “The Controversial Role of Lamivudine Prophylaxis in Occult HBV Carriers Treated with Chemo-Immune Therapy.” Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 41, no. 11, Nov. 2009, pp. 839–40. EBSCOhost, https://doi.org/10.1016/j.dld.2009.03.002.

APA

D’Andrea, M., Nosotti, L., Pimpinelli, F., Dessanti, M. L., Paviglianiti, A., Miglioresi, L., Morrone, A., & Petti, M. C. (2009). The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 41(11), 839–840. https://doi.org/10.1016/j.dld.2009.03.002

Chicago

D’Andrea, M, L Nosotti, F Pimpinelli, M L Dessanti, A Paviglianiti, L Miglioresi, A Morrone, and M C Petti. 2009. “The Controversial Role of Lamivudine Prophylaxis in Occult HBV Carriers Treated with Chemo-Immune Therapy.” Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 41 (11): 839–40. doi:10.1016/j.dld.2009.03.002.